CTLA4 and melanoma: Nonetheless, Ipilimumab (targeting Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)) showed an impressive improvement in overall survival in adult patients with advanced melanoma and became the first FDA approved immune checkpoint inhibitor in 2010 [14].